Patent Application
20120264634
The present invention relates to novel marker sequences for pancreatic cancer diseases, pancreatic carcinoma, and the diagnostic use thereof together with a method for screening potential active substances for pancreatic cancer diseases of this type by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing marker sequences of this type for pancreatic cancer diseases, pancreatic carcinoma, in particular a protein biochip and the use thereof
The 5-year-survival rate for pancreatic carcinoma of approx. 1% is the lowest of all cancer types (Parkin, D. M., F. Bray, et al. (2001). “Estimating the world cancer burden: Globocan 2000.” Int J Cancer 94(2): 153-6). Early diagnosis might increase the 5-year survival rate to 40% (Yeo, C. J. and J. L. Cameron (1998). “Prognostic factors in ductal pancreatic cancer.” Langenbecks Arch Surg 383(2): 129-33). Therefore, for diagnosis, the precursor diseases of pancreatic cancer need to be considered as well, such as PDAC (pancreatic ductal adenocarcinoma), PanIN (pancreatic intraepithelial neoplasias), pancreatic lesions, CP (chronic pancreatitis), including endocrine tumors of the pancreas. Especially PanID are associated with pancreatic lesions and differentiate them morphologically into PanIn 1A, 1B, 2, and 3 (Kern, S., R. Hruban, et al. (2001). “A white paper: the product of a pancreas cancer think tank.” Cancer Res 61(12): 4923-32). Pancreatic lesions have also been described for CP. Endocrine (benign or malignant) tumors of the pancreas, particularly neuroendocrine tumors, are relevant as well.
WO2008064670 describes e.g. marker genes for pancreas obtained by means of proteome analysis and histological investigations.
Protein biochips are gaining increasing industrial importance in analysis and diagnosis as well as in pharmaceutical development. Protein biochips have become established as screening instruments.
The rapid and highly parallel detection of a multiplicity of specifically binding analysis molecules in a single experiment is rendered possible hereby. To produce protein biochips, it is necessary to have the required proteins available. For this purpose, in particular protein expression libraries have become established. The high throughput cloning of defined open reading frames is one possibility (Heyman, J. A., Cornthwaite, J., Foncerrada, L., Gilmore, J. R., Gontang, E., Hartman, K. J., Hernandez, C. L., Hood, R., Hull, H. M., Lee, W. Y., Marcil, R., Marsh, E. J., Mudd, K. M., Patino, M. J., Purcell, T. J., Rowland, J. J., Sindici, M. L. and Hoeffler, J. P., (1999) Genome-scale cloning and expression of individual open reading frames using topoisomerase I-mediated ligation. Genome Res, 9, 383-392; Kersten, B., Feilner, T., Kramer, A., Wehrmeyer, S., Possling, A., Witt, I., Zanor, M. I., Stracke, R., Lueking, A., Kreutzberger, J., Lehrach, H. and Cahill, D. J. (2003) Generation of Arabidopsis protein chip for antibody and serum screening. Plant Molecular Biology, 52, 999-1010; Reboul, J., Reboul, J., Vaglio, P., Rual, J. F., Lamesch, P., Martinez, M., Armstrong, C M., Li, S., Jacotot, L., Bertin, N., Janky, R., Moore, T., Hudson, J. R., Jr., Hartley, J. L., Brasch, M. A., Vandenhaute, J., Boulton, S., Endress, G. A., Jenna, S., Chevet, E., Papasotiropoulos, V., Tolias, P. P., Ptacek, J., Snyder, M., Huang, R., Chance, M. R., Lee, H., Doucette-Stamm, L., Hill, D. E. and Vidal, M. (2003) C. elegans ORFeome Version 1.1: experimental verification of the genome annotation and resource for proteome-scale protein expression. Nat Genet, 34, 35-41.; Walhout, A. J., Temple, G. F., Brasch, M. A., Hartley, J. L., Lorson, M. A. , van den Heuvel, S. and Vidal, M. (2000) GATEWAY recombinational cloning: application to the cloning of large numbers of open reading frames or ORFeomes. Methods Enzymol, 328, 575-592). However, an approach of this type is strongly connected to the progress of the genome sequencing projects and the annotation of these gene sequences. Furthermore, the determination of the expressed sequence can be ambiguous due to differential splicing processes. This problem may be circumvented by the application of cDNA expression libraries (Büssow, K., Cahill, D., Nietfeld, W., Bancroft, D., Scherzinger, E., Lehrach, H. and Walter, G. (1998) A method for global protein expression and antibody screening on high-density filters of an arrayed cDNA library. Nucleic Acids Research, 26, 5007-5008; Büssow, K., Nordhoff, E., Lübbert, C, Lehrach, H. and Walter, G. (2000) A human cDNA library for high-throughput protein expression screening. Genomics, 65, 1-8; Holz, C, Lueking, A., Bovekamp, L., Gutjahr, C, Bolotina, N., Lehrach, H. and Cahill, D. J. (2001) A human cDNA expression library in yeast enriched for open reading frames. Genome Res, 11, 1730-1735; Lueking, A., Holz, C, Gotthold, C, Lehrach, H. and Cahill, D. (2000) A system for dual protein expression in Pichia pastoris and Escherichia coli, Protein Expr. Purif., 20, 372-378). The cDNA of a particular tissue is hereby cloned into a bacterial or an eukaryotic expression vector, such as, e.g., yeast. The vectors used for the expression are generally characterized in that they carry inducible promoters that may be used to control the time of protein expression. Furthermore, expression vectors have sequences for so-called affinity epitopes or affinity proteins, which on the one hand permit the specific detection of the recombinant fusion proteins by means of an antibody directed against the affinity epitope, and on the other hand the specific purification via affinity chromatography (IMAC) is rendered possible.
For example, the gene products of a cDNA expression library from human fetal brain tissue in the bacterial expression system Escherichia coli were arranged in high-density format on a membrane and could be successfully screened with different antibodies. It was possible to show that the proportion of full-length proteins is at least 66%. Additionally, the recombinant proteins from the library could be expressed and purified in a high-throughput manner (Braun P., Hu, Y., Shen, B., Halleck, A., Koundinya, M., Harlow, E. and LaBaer, J. (2002) Proteome-scale purification of human proteins from bacteria. Proc Natl Acad Sci USA, 99, 2654-2659; Büssow (2000) supra; Lueking, A., Horn, M., Eickhoff, H., Büssow, K., Lehrach, H. and Walter, G. (1999) Protein microarrays for gene expression and antibody screening. Analytical Biochemistry, 270, 103-111). Protein biochips of this type based on cDNA expression libraries are in particular the subject matter of WO 99/57311 and WO 99/57312.
Furthermore, in addition to antigen-presenting protein biochips, antibody-presenting arrangements are likewise described (Lal et al (2002) Antibody arrays: An embryonic but rapidly growing technology, DDT, 7, 143-149; Kusnezow et al. (2003), Antibody microarrays: An evaluation of production parameters, Proteomics, 3, 254-264).
Protein-biochips have a advantageously high sensitivity.
However, there is a great need to provide indication-specific diagnostic devices, such as a protein biochip.
The object of the present invention is therefore to provide improved marker sequences and the diagnostic use thereof for the treatment of pancreatic cancer diseases up to pancreatic carcinoma.
The object of the present invention is solved in providing of novel marker sequences SEQ 1-1004, which are identified for the first time by means of a protein biochip, in particular including bioinformatic analysis. Therefore, SEQ 1-1004 are identified for the first time by means of a protein biochip.
The provision of specific marker sequences permits a reliable diagnosis and stratification of patients with pancreatic cancer diseases up to pancreatic carcinoma, in particular by means of a protein biochip.
The invention therefore relates to the use of marker sequences for the diagnosis of pancreatic cancer diseases up to pancreatic carcinoma, wherein at least one marker sequence of a cDNA selected from the group SEQ 1-1004 or respectively a protein coding therefor or respectively a partial sequence or fragment thereof (hereinafter: marker sequences according to the invention) is determined on or from a patient to be examined
It was possible to identify the marker sequences according to the invention by means of differential screening of samples from healthy test subjects with patient samples with pancreatic cancer diseases, pancreatic carcinoma.
The term “pancreatic cancer diseases up to pancreatic carcinoma” in accordance with the invention encompasses also precursor and/or concomitant illnesses thereof, pancreatic cancer diseases and/or pancreatic carcinoma as such, however in particular PDAC (Pancreatic ductal adenocarcinoma), PanIN (pancreatic intraepithelial neoplasias), pancreatic lesions, CP (chronic pancreatitis), including endocrine pancreatic tumors, particularly pancreatic tumors and pancreatic neoplasm (definition, e.g., according to Pschyrembel, de Gruyter, 261st edition (2007), Berlin).
In a further embodiment at least 2 to 5 or 10, preferably 30 to 50 marker sequences, or 50 to 100 or more marker sequences are determined on or from a patient to be examined
In a further embodiment of the invention, the marker sequences according to the invention can likewise be combined, supplemented, fused, or expanded likewise with known biomarkers for this indication.
In a preferred embodiment, the determination of the marker sequences is carried out outside the human body and the determination is carried out in an ex vivo/in vitro diagnosis.
In a further embodiment of the invention, the invention relates to the use of marker sequences as diagnostic agents, wherein at least one marker sequence of a cDNA is selected from the group SEQ 1-1004, preferably SEQ 503-1004, or respectively a protein coding therefor or respectively a partial sequence or fragment thereof.
Furthermore, the invention relates to a method for the diagnosis of pancreatic cancer diseases up to pancreatic carcinoma, wherein a.) at least one marker sequence of a cDNA selected from the group SEQ 1-1004, preferably SEQ 503-1004, or respectively a protein coding therefor or respectively a partial sequence or fragment thereof is applied to a solid support and b.) is brought into contact with body fluid or tissue extract of a patient and c.) the detection of an interaction of the body fluid or tissue extract with the marker sequences from a.) is carried out.
The invention therefore likewise relates to diagnostic agents for the diagnosis of pancreatic cancer diseases up to pancreatic carcinoma respectively selected from the group SEQ 1-1004, preferably SEQ 503-1004, or respectively a protein coding therefor or respectively a partial sequence or fragment thereof
The detection of an interaction of this type can be carried out, for example, by a probe, in particular by an antibody.
The invention therefore likewise relates to the object of providing a diagnostic device or an assay, in particular a protein biochip, which permits a diagnosis or examination for pancreatic cancer diseases up to pancreatic carcinoma.
Furthermore, the invention relates to a method for the stratification, in particular risk stratification and/or therapy control of a patient with pancreatic cancer diseases up to pancreatic carcinoma, wherein at least one marker sequence of a cDNA selected from the group 1-1004, preferably SEQ 503-1004, or respectively a protein coding therefor is determined on a patient to be examined
Furthermore, the stratification of the patients with pancreatic cancer diseases up to pancreatic carcinoma in new or established subgroups of inflammatory pancreatic cancer diseases up to pancreatic carcinoma is also covered, as well as the expedient selection of patient groups for the clinical development of novel therapeutic agents. The term therapy control likewise covers the allocation of patients to responders and non-responders regarding a therapy or the therapy course thereof.
“Diagnosis” for the purposes of this invention means the positive determination of pancreatic cancer diseases up to pancreatic carcinoma by means of the marker sequences according to the invention as well as the assignment of the patients to pancreatic cancer diseases up to pancreatic carcinoma. The term diagnosis covers medical diagnostics and examinations in this regard, in particular in-vitro diagnostics and laboratory diagnostics, likewise proteomics and nucleic acid blotting. Further tests can be necessary to be sure and to exclude other diseases. The term diagnosis therefore likewise covers the differential diagnosis of pancreatic cancer diseases, pancreatic carcinoma by means of the marker sequences according to the invention and the prognosis of pancreatic cancer diseases, pancreatic carcinoma.
“Stratification or therapy control” for the purposes of this invention means that the method according to the invention renders possible decisions for the treatment and therapy of the patient, whether it is the hospitalization of the patient, the use, effect and/or dosage of one or more drugs, a therapeutic measure or the monitoring of a course of the disease and the course of therapy or etiology or classification of a disease, e.g., into a new or existing subtype or the differentiation of diseases and the patients thereof
In a further embodiment of the invention, the term “stratification” covers in particular the risk stratification with the prognosis of an outcome of a negative health event.
Within the scope of this invention, “patient” means any test subject—human or mammal—with the proviso that the test subject is tested for pancreatic cancer diseases up to pancreatic carcinoma.
The term “marker sequences” for the purposes of this invention means that the cDNA or the polypeptide or protein that can be respectively obtained therefrom are significant for pancreatic cancer diseases, pancreatic carcinoma. For example, the cDNA or the polypeptide or protein that can be respectively obtained therefrom can exhibit an interaction with substances from the body fluid or tissue extract of a patient with pancreatic cancer diseases, pancreatic carcinoma (e.g., antigen (epitope)/antibody (paratope) interaction). For the purposes of the invention “wherein at least one marker sequence of a cDNA selected from the group SEQ 1-1004, preferably SEQ 503-1004 or respectively a protein coding therefor or respectively a partial sequence or fragment thereof is determined on a patient to be examined” means that an interaction between the body fluid or tissue extract of a patient and the marker sequences according to the invention is detected. An interaction of this type is, e.g., a bond, in particular a binding substance on at least one marker sequence according to the invention or in the case of a cDNA the hybridization with a suitable substance under selected conditions, in particular stringent conditions (e.g., such as usually defined in J. Sambrook, E. F. Fritsch, T. Maniatis (1989), Molecular cloning: A laboratory manual, 2nd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA or Ausubel, “Current Protocols in Molecular Biology,” Green Publishing Associates and Wiley Interscience, N.Y. (1989)). One example of stringent hybridization conditions is: hybridization in 4×SSC at 65° C. (alternatively in 50% formamide and 4×SSC at 42° C.), followed by several washing steps in 0.1×SSC at 65° C. for a total of approximately one hour. An example of less stringent hybridization conditions is hybridization in 4×SSC at 37° C., followed by several washing steps in 1×SSC at room temperature.
According to the invention, substances of this type are constituents of a body fluid, in particular blood, whole blood, blood plasma, blood serum, patient serum, urine, cerebrospinal fluid, synovial fluid, or of a tissue extract of the patient.
In a further embodiment of the invention, however, the marker sequences according to the invention can be present in a significantly higher or lower expression rate or concentration that indicates pancreatic cancer diseases, pancreatic carcinoma. The relative sick/healthy expression rates of the marker sequences for pancreatic cancer diseases, pancreatic carcinoma according to the invention are hereby determined by means of a protein biochip according to the invention.
In a further embodiment of the invention, the marker sequences have a recognition signal that is addressed to the substance to be bound (e.g., antibody, nucleic acid). It is preferred according to the invention that for a protein the recognition signal is an epitope and/or a paratope and/or a hapten and for a cDNA is a hybridization or binding region.
The marker sequences according to the invention are the subject matter of Table A and can be clearly identified by the respectively cited database entry (also by means of the Internet: http://www.ncbi.nlm.nih.gov/) (see in Table A), see also the associated sequence protocol.
The sequences 1 to 502 relate to the full-length sequences of the sequences 503 to 1004. The sequences 503 to 1004 are preferred sequences, which are identified directly from the protein biochip according to the invention.
According to the invention, the marker sequences also cover those modifications of the cDNA sequence and the corresponding amino acid sequence as chemical modification, such as citrullination, acetylation, phosphorylation, glycosylation or poly(A) strand and other modifications known to one skilled in the art.
In a further embodiment of the invention, partial sequences or fragments of the marker sequences according to the invention are likewise comprised. In particular those partial sequences that have an identity of 95%, 90%, in particular 80% or 70% with the marker sequences according to the invention.
Such partial sequences or fragments of the marker sequences according to the invention are defined by function and have the same diagnostic function.
Partial sequences are also sequences of the type which have 50 to 100 nucleotides, 70-120 nucleotides of a sequence of the SEQ 1-1004, preferably SEQ 503-1004, or peptides obtainable therefrom.
In a further embodiment, the respective marker sequence can be represented in different quantities in one more regions on a solid support. This permits a variation of the sensitivity.
The regions can have respectively a totality of marker sequences, i.e., a sufficient number of different marker sequences, in particular 2 to 5 or 10 or more and optionally more nucleic acids and/or proteins, in particular biomarkers. However, at least 96 to 25,000 (numerical) or more from different or identical marker sequences and further nucleic acids and/or proteins, in particular biomarkers are preferred. Furthermore preferred are more than 2,500, in particular preferred 10,000 or more different or identical marker sequences and optionally further nucleic acids and/or proteins, in particular biomarkers.
Another object of the invention relates to an arrangement of marker sequences containing at least one marker sequence of a cDNA selected from the group SEQ 1-1004, preferably SEQ 503-1004 or respectively a protein coding therefor. Preferably, the arrangement contains at least 2 to 5 or 10, preferably 30 to 50 marker sequences, or 50 to 100 or more marker sequences.
Within the scope of this invention, “arrangement” is synonymous with “array,” and if this “array” is used to identify substances on marker sequences, this is to be understood to be an “assay” or diagnostic device. In a preferred embodiment, the arrangement is designed such that the marker sequences represented on the arrangement are present in the form of a grid on a solid support. Furthermore, those arrangements are preferred that permit a high-density arrangement of protein binders and the marker sequences are spotted. Such high-density spotted arrangements are disclosed, for example, in WO 99/57311 and WO 99/57312 and can be used advantageously in a robot-supported automated high-throughput method.
Within the scope of this invention, however, the term “assay” or diagnostic device likewise comprises those embodiments of a device, such as ELISA, bead-based assay, line assay, Western Blot, immunochromatographic methods (e.g., so-called lateral flow immunoassays, or similar immunological single or multiplex detection measures. A protein biochip in terms of this invention is the systematic arrangement of proteins on a solid support.
The marker sequences of the arrangement are fixed on a solid support, but preferably spotted or immobilized even printed on, i.e. applied in a reproducible manner. One or more marker sequences can be present multiple times in the totality of all marker sequences and present in different quantities based on one spot. Furthermore, the marker sequences can be standardized on the solid support (i.e., by means of serial dilution series of, e.g., human globulins as internal calibrators for data normalization and quantitative evaluation).
The invention therefore relates to an assay or a protein biochip comprising an arrangement containing marker sequences according to the invention.
In a further embodiment, the marker sequences are present as clones. Clones of this type can be obtained, for example, by means of a cDNA expression library according to the invention (Büssow et al. 1998 (supra)). In a preferred embodiment, such expression libraries containing clones are obtained using expression vectors from a cDNA expression library comprising the cDNA marker sequences. These expression vectors preferably contain inducible promoters. The induction of the expression can be carried out, e.g., by means of an inductor, such as IPTG. Suitable expression vectors are described in Terpe et al. (Terpe T Appl Microbiol Biotechnol. 2003 January; 60(5): 523-33).
One skilled in the art is familiar with expression libraries, they can be produced according to standard works, such as Sambrook et al, “Molecular Cloning, A laboratory handbook, 2nd edition (1989), CSH press, Cold Spring Harbor, N.Y. Expression libraries are also preferred which are tissue-specific (e.g., human tissue, in particular human organs).
Furthermore included according to the invention are expression libraries that can be obtained by exon-trapping. A synonym for expression library is expression bank.
Also preferred are protein biochips or corresponding expression libraries that do not exhibit any redundancy (so-called: Uniclone® library) and that may be produced, for example, according to the teachings of WO 99/57311 and WO 99/57312. These preferred Uniclone libraries have a high portion of non-defective fully expressed proteins of a cDNA expression library.
Within the context of this invention, the clones can also be, but not limited to, transformed bacteria, recombinant phages, or transformed cells from mammals, insects, fungi, yeasts, or plants.
The clones are fixed, spotted, or immobilized on a solid support.
The invention therefore relates to an arrangement wherein the marker sequences are present as clones.
Additionally, the marker sequences can be present in the respective form of a fusion protein, which contains, for example, at least one affinity epitope or tag. The tag may be one such as contains c-myc, his tag, arg tag, FLAG, alkaline phosphatase, VS tag, T7 tag or strep tag, HAT tag, NusA, S tag, SBP tag, thioredoxin, DsbA, a fusion protein, preferably a cellulose-binding domain, green fluorescent protein, maltose-binding protein, calmodulin-binding protein, glutathione S-transferase, or lacZ.
In all of the embodiments, the term “solid support” covers embodiments such as a filter, a membrane, a magnetic or fluorophore-labeled bead, a silica wafer, glass, metal, ceramics, plastics, a chip, a target for mass spectrometry, or a matrix. However, a filter is preferred according to the invention.
As a filter, furthermore PVDF, nitrocellulose, or nylon is preferred (e.g, Immobilon P Millipore, Protran Whatman, Hybond N+ Amersham).
In another preferred embodiment of the arrangement according to the invention, the arrangement corresponds to a grid with the dimensions of a microtiter plate (8-12 wells strips, 96 wells, 384 wells, or more), a silica wafer, a chip, a target for mass spectrometry, or a matrix.
In a further embodiment, the invention relates to an assay or a protein biochip for identifying and characterizing a substance for pancreatic cancer diseases, pancreatic carcinoma, characterized in that an arrangement or assay according to the invention is a.) brought into contact with at least one substance to be tested and b.) a binding success is detected.
Furthermore, the invention relates to a method for identifying and characterizing a substance for pancreatic cancer diseases, pancreatic carcinoma, characterized in that an arrangement or assay according to the invention is a.) brought into contact with at least one substance to be tested and b.) a binding success is detected.
The substance to be tested can be any native or non-native biomolecule, a synthetic chemical molecule, a mixture, or a substance library.
After the substance to be tested contacts a marker sequence, the binding success is evaluated, which, for example, is carried out using commercially available image analyzing software (GenePix Pro (Axon Laboratories), Aida (Ray test), ScanArray (Packard Bioscience)).
The visualization of protein-protein interactions according to the invention (e.g., protein on marker sequence, as antigen/antibody) or corresponding “means for detecting the binding success” can be performed, for example, using fluorescence labeling, biotinylation, radioisotope labeling, or colloid gold or latex particle labeling in the usual way. A detection of bound antibodies is carried out with the aid of secondary antibodies, which are labeled with commercially available reporter molecules (e.g., Cy, Alexa, Dyomics, FITC, or similar fluorescent dyes, colloidal gold or latex particles), or with reporter enzymes, such as alkaline phosphatase, horseradish peroxidase, etc., and the corresponding colorimetric, fluorescent, or chemiluminescent substrates. Readout is conducted, e.g., using a microarray laser scanner, a CCD camera, or visually.
In a further embodiment, the invention relates to a drug/active substance or prodrug developed for pancreatic cancer diseases, pancreatic carcinoma and obtainable through the use of the assay or protein biochip according to the invention.
The invention therefore likewise relates to the use of an arrangement according to the invention or an assay for screening active substances for pancreatic cancer diseases, pancreatic carcinoma.
In a further embodiment, the invention therefore likewise relates to a target for the treatment and therapy of pancreatic cancer diseases, pancreatic carcinoma respectively selected from the group SEQ 1-1004, preferably SEQ 503-1004, or a protein respectively coding therefor.
In a further embodiment, the invention likewise relates to the use of the marker sequences according to the invention, preferably in the form of an arrangement, as an affinity material for carrying out an apheresis or in the broadest sense a blood lavage, wherein substances from body fluids of a patient with pancreatic cancer diseases, pancreatic carcinoma, such as blood or plasma, bind to the marker sequences according to the invention and consequently can be selectively withdrawn from the body fluid.
Ten or more patient samples were individually screened against a cDNA expression library. The expression clones specific to pancreatic cancer diseases, pancreatic carcinoma were determined through a comparison with ten or more healthy samples. The identity of the marker sequences was determined by DNA sequencing.
In the scope of the biomarker identification, various bioinformatic analyses are performed. For each serum, reactivities against approximately 2000 different antigens are measured by means of microarray. These data are used for a ranking of the spotted antigens with respect to their differentiation capability between healthy and diseased sera. This analysis is performed by means of the non-parameterized Mann-Whitney test on normalized intensity data. An internal standard which is also spotted on each chip is used for the normalization. Since a p value is calculated for each antigen, methods are used for correction of the multiple test. As a very conservative approach, a Bonferroni direction is performed and the less restrictive false discovery rate (FDR) according to Benjamini & Hochberg is additionally calculated. Furthermore, the data are used for classification of the sera. Different multivariate methods are used hereby. These are methods from statistical learning methods such as support vector machines (SVM), neural networks, or classification trees, as well as a threshold value method, which is capable of both classification and also visual representation of the data.
To avoid overfitting, a 10-fold cross-validation of the data is performed.
Homo sapiens ring finger protein 24 (RNF24), mRNA
Homo sapiens IK cytokine, down-regulator of HLA II (IK), mRNA
Homo sapiens NHS-like 1, transcript variant 5 (NHSL1), mRNA
Homo sapiens SHC (Src homology 2 domain containing) transforming protein 2 (SHC2), mRNA
Homo sapiens hypothetical protein FLJ14668 (FLJ14668), mRNA
Homo sapiens smoothelin (SMTN), transcript variant 2, mRNA
Homo sapiens homer homolog 3 (Drosophila) (HOMER3), mRNA
Homo sapiens malate dehydrogenase 2, NAD (mitochondrial) (MDH2), mRNA
Homo sapiens RAS, dexamethasone-induced 1 (RASD1), mRNA
Homo sapiens calcineurin binding protein 1 (CABIN1), mRNA
Homo sapiens LIM domain containing 2 (LIMD2), mRNA
Homo sapiens eomesodermin homolog (Xenopus laevis) (EOMES), mRNA
Homo sapiens zinc finger protein 786 (ZNF786), mRNA
Homo sapiens isocitrate dehydrogenase 2 (NADP+), mitochondrial (IDH2), mRNA
Homo sapiens adducin 1 (alpha) (ADD1), transcript variant 3, mRNA
Homo sapiens chromosome 10 open reading frame 13 (C10orf13), mRNA
Homo sapiens MARCKS-like 1 (MARCKSL1), mRNA
Homo sapiens coiled-coil domain containing 102A (CCDC102A), mRNA
Homo sapiens zinc finger protein 447 (ZNF447), mRNA
Homo sapiens required for meiotic nuclear division 5 homolog B (S. cerevisiae) (RMND5B),
Homo sapiens dehydrogenase/reductase (SDR family) member 13 (DHRS13), mRNA
Homo sapiens proteasome (prosome, macropain) 26S subunit, non-ATPase, 9 (PSMD9), mRNA
Homo sapiens phosphatidylinositol 3,4,5-trisphosphate-dependent RAC exchanger 1 (PREX1),
Homo sapiens coatomer protein complex, subunit gamma (COPG), mRNA
Homo sapiens chromosome 5 genomic contig, reference assembly
Homo sapiens chromosome 10 genomic contig, reference assembly
Homo sapiens splA/ryanodine receptor domain and SOCS box containing 3 (SPSB3), mRNA
Homo sapiens sorcin (SRI), transcript variant 1, mRNA
Homo sapiens OTU domain containing 5 (OTUD5), mRNA
Homo sapiens hypothetical protein MGC11257 (MGC11257), mRNA
Homo sapiens solute carrier family 38, member 3 (SLC38A3), mRNA
Homo sapiens calcium channel, voltage-dependent, beta 1 subunit (CACNB1), transcript variant
Homo sapiens dihydrouridine synthase 1-like (S. cerevisiae) (DUS1L), mRNA
Homo sapiens vacuolar protein sorting 35 (yeast) (VPS35), mRNA
Homo sapiens calsyntenin 3 (CLSTN3), mRNA
Homo sapiens pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1)
Homo sapiens phosphomannomutase 1 (PMM1), mRNA
Homo sapiens reticulocalbin 2, EF-hand calcium binding domain (RCN2), mRNA
Homo sapiens ribosomal protein S8 (RPS8), mRNA
Homo sapiens coiled-coil-helix-coiled-coil-helix domain containing 8 (CHCHD8), mRNA
Homo sapiens family with sequence similarity 53, member 8 (FAM53B), mRNA
Homo sapiens protein kinase, AMP-activated, gamma 1 non-catalytic subunit (PRKAG1),
Homo sapiens immunoglobulin (CD79A) binding protein 1 (IGBP1), mRNA
Homo sapiens chromosome 6 genomic contig, reference assembly
Homo sapiens CXXC finger 1 (PHD domain) (CXXC1), mRNA
Homo sapiens adenomatosis polyposis coli (APC), mRNA
Homo sapiens calcyclin binding protein (CACYBP), transcript variant 1, mRNA
Homo sapiens zinc finger protein 44 (ZNF44), mRNA
Homo sapiens protein phosphatase 1, catalytic subunit, alpha isoform (PPP1CA), transcript
Homo sapiens KIAA0100 (KIAA0100), mRNA
Homo sapiens tubulin tyrosine ligase-like family, member 12 (TTLL12), mRNA
Homo sapiens nuclear receptor coactivator 5 (NCOA5), mRNA
Homo sapiens p53-associated parkin-like cytoplasmic protein (PARC), mRNA
Homo sapiens ATPase, Class II, type 9A (ATP9A), mRNA
Homo sapiens CD74 molecule, major histocompatibility complex, class II invariant chain (CD74),
Homo sapiens praja 1 (PJA1), transcript variant 2, mRNA
Homo sapiens chromosome 20 open reading frame 45 (C20orf45), mRNA
Homo sapiens chromosome 9 open reading frame 78 (C9orf78), transcript variant 2, mRNA
Homo sapiens endoplasmic reticulum protein 29 (ERP29), transcript variant 1, mRNA
Homo sapiens engulfment and cell motility 1 (ELMO1), transcript variant 2, mRNA
Homo sapiens chromosome 1 genomic contig, reference assembly
Homo sapiens chromosome 4 genomic contig, alternate assembly (based on Celera assembly)
Homo sapiens synaptotagmin V (SYT5), mRNA
Homo sapiens endothelial cell-specific chemotaxis regulator (ECSCR), mRNA
Homo sapiens hypothetical protein LOC65998 (LOC65998), mRNA
Homo sapiens odz, odd Oz/ten-m homolog 4 (Drosophila) (ODZ4), mRNA
Homo sapiens chromosome 12 open reading frame 51 (C12orf51), mRNA
Homo sapiens chromosome 16 open reading frame 88 (C16orf88), mRNA
Homo sapiens ubiquitin specific peptidase 22 (USP22), mRNA
Homo sapiens structural maintenance of chromosomes flexible hinge domain containing 1
Homo sapiens KIAA1543 (KIAA1543), mRNA
Homo sapiens serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium
Homo sapiens zinc finger protein 235 (ZNF235), mRNA
Homo sapiens bromodomain containing 3 (BRD3), mRNA
Homo sapiens X-ray repair complementing defective repair in Chinese hamster cells 5 (double-
Homo sapiens intercellular adhesion molecule 3 (ICAM3), mRNA
Homo sapiens fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism)
Homo sapiens fibronectin type III and SPRY domain containing 1 (FSD1), mRNA
Homo sapiens transmembrane protein 43 (TMEM43), mRNA
Homo sapiens zinc finger, DHHC-type containing 11 (ZDHHC11), mRNA
Homo sapiens zinc finger protein 671 (ZNF671), mRNA
Homo sapiens chromosome 6 open reading frame 134 (C6orf134), transcript variant 2, mRNA
Homo sapiens L1 cell adhesion molecule (L1CAM), transcript variant 2, mRNA
Homo sapiens hypothetical protein FLJ22795 (FLJ22795), mRNA
Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 (DDX5), mRNA
Homo sapiens transmembrane protein induced by tumor necrosis factor alpha (TMPIT), mRNA
Homo sapiens methionine-tRNA synthetase (MARS), mRNA
Homo sapiens protocadherin beta 7 (PCDHB7), mRNA
Homo sapiens protocadherin gamma subfamily A, 11 (PCDHGA11), transcript variant 1, mRNA
Homo sapiens Mov10, Moloney leukemia virus 10, homolog (mouse) (MOV10), mRNA
Homo sapiens alanine-glyoxylate aminotransferase 2-like 2 (AGXT2L2), transcript variant 1,
Homo sapiens protocadherin 12 (PCDH12), mRNA
Homo sapiens poly(rC) binding protein 4 (PCBP4), transcript variant 4, mRNA
Homo sapiens tripartite motif-containing 28 (TRIM28), mRNA
Homo sapiens ribosomal protein L10 (RPL10), mRNA
Homo sapiens mitochondrial ribosomal protein S24 (MRPS24), nuclear gene encoding
Homo sapiens ribosomal protein L31 (RPL31), mRNA
Homo sapiens enolase 1, (alpha) (ENO1), mRNA
Homo sapiens adaptor-related protein complex 1, sigma 1 subunit (AP1S1), transcript variant 1,
Homo sapiens cyclin D2 (CCND2), mRNA
Homo sapiens cyclin-dependent kinase 7 (MO15 homolog, Xenopus laevis, cdk-activating kinase)
Homo sapiens kelch domain containing 3 (KLHDC3), mRNA
Homo sapiens phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole
Homo sapiens wingless-type MMTV integration site family, member 7B (WNT7B), mRNA
Homo sapiens zinc finger protein 354B (ZNF354B), mRNA
Homo sapiens vacuolar protein sorting 16 (yeast) (VPS16), transcript variant 3, mRNA
Homo sapiens fuse-binding protein-interacting repressor (SIAHBP1), transcript variant 1, mRNA
Homo sapiens adaptor-related protein complex 1, mu 1 subunit (AP1M1), mRNA
Homo sapiens vacuolar protein sorting 33B (yeast) (VPS33B), mRNA
Homo sapiens glucose phosphate isomerase (GPI), mRNA
Homo sapiens HLA-B associated transcript 3 (BAT3), transcript variant 2, mRNA
Homo sapiens drebrin 1 (DBN1), transcript variant 1, mRNA
Homo sapiens centaurin, gamma-like family, member 1 (CTGLF1), mRNA
Homo sapiens stem-loop (histone) binding protein (SLBP), mRNA
Homo sapiens SUB1 homolog (S. cerevisiae) (SUB1), mRNA
Homo sapiens tetracycline transporter-like protein (TETRAN), mRNA
Homo sapiens WD repeat domain 77 (WDR77), mRNA
Homo sapiens ras homolog gene family, member T2 (RHOT2), mRNA
Homo sapiens zinc finger, AN1-type domain 2B (ZFAND2B), mRNA
Homo sapiens alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S.
cerevisiae) (ATRX), transcript variant 2, mRNA
Homo sapiens cortactin (CTTN), transcript variant 2, mRNA
Homo sapiens chromosome 20 genomic contig, reference assembly
Homo sapiens mitogen-activated protein kinase 7 (MAPK7), transcript variant 2, mRNA
Homo sapiens mitogen-activated protein kinase 8 interacting protein 1 (MAPK8IP1), mRNA
Homo sapiens diacylglycerol lipase beta (DAGLBETA), mRNA
Homo sapiens component of oligomeric golgi complex 4 (COG4), mRNA
Homo sapiens stromal interaction molecule 1 (STIM1), mRNA
Homo sapiens tetraspanin 8 (TSPAN8), mRNA
Homo sapiens solute carrier family 4, anion exchanger, member 2 (erythrocyte membrane protein
Homo sapiens pleckstrin homology domain containing, family O member 1 (PLEKHO1), mRNA
Homo sapiens family with sequence similarity 108, member A1 (FAM108A1), mRNA
Homo sapiens coiled-coil domain containing 115 (CCDC115), mRNA
Homo sapiens transmembrane protein 55B (TMEM55B), mRNA
Homo sapiens Ion peptidase 1, mitochondrial (LONP1), nuclear gene encoding mitochondrial
Homo sapiens membrane protein, palmitoylated 3 (MAGUK p55 subfamily member 3) (MPP3),
Homo sapiens proline-rich transmembrane protein 2 (PRRT2), mRNA
Homo sapiens mitogen-activated protein kinase kinase kinase 10 (MAP3K10), mRNA
Homo sapiens tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta
Homo sapiens tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta
Homo sapiens amyloid beta (A4) precursor protein-binding, family B, member 1 (Fe65) (APBB1),
Homo sapiens amyloid beta (A4) precursor protein-binding, family B, member 1 (Fe65) (APBB1),
Homo sapiens BRF2, subunit of RNA polymerase III transcription initiation factor, BRF1-like
Homo sapiens oxysterol binding protein-like 5 (OSBPL5), transcript variant 1, mRNA
Homo sapiens phosphoglycerate kinase 1 (PGK1), mRNA
Homo sapiens immunoglobulin superfamily, member 4 (IGSF4), mRNA
Homo sapiens WD and tetratricopeptide repeats 1 (WDTC1), mRNA
Homo sapiens exportin 7 (XPO7), mRNA
Homo sapiens proteasome (prosome, macropain) subunit, beta type, 2 (PSMB2), mRNA
Homo sapiens F-box and leucine-rich repeat protein 8 (FBXL8), mRNA
Homo sapiens serine hydroxymethyltransferase 1 (soluble) (SHMT1), transcript variant 1, mRNA
Homo sapiens chromosome 17 open reading frame 45 (C17orf45), mRNA
Homo sapiens tumor necrosis factor, alpha-induced protein 8-like 1 (TNFAIP8L1), mRNA
Homo sapiens actin related protein 2/3 complex, subunit 1A, 41 kDa (ARPC1A), mRNA
Homo sapiens sorting nexin 4 (SNX4), mRNA
Homo sapiens NOL1/NOP2/Sun domain family, member 5 (NSUN5), transcript variant 2, mRNA
Homo sapiens leukocyte receptor cluster (LRC) member 4 (LENG4), mRNA
Homo sapiens transportin 1 (TNPO1), transcript variant 2, mRNA
Homo sapiens MCM5 minichromosome maintenance deficient 5, cell division cycle 48 (S.
cerevisiae) (MCM5), mRNA
Homo sapiens N-acylaminoacyl-peptide hydrolase (APEH), mRNA
Homo sapiens chromosome 20 open reading frame 96 (C20orf96), mRNA
Homo sapiens ubiquitin specific peptidase 10 (USP10), mRNA
Homo sapiens RGM domain family, member A (RGMA), mRNA
Homo sapiens BR serine/threonine kinase 1 (BRSK1), mRNA
Homo sapiens tetratricopeptide repeat domain 5 (TTC5), mRNA
Homo sapiens proteasome (prosome, macropain) 26S subunit, ATPase, 1 (PSMC1), mRNA
Homo sapiens coiled-coil and C2 domain containing 1A (CC2D1A), mRNA
Homo sapiens SH3-domain GRB2-like endophilin B2 (SH3GLB2), mRNA
Homo sapiens kelch-like 22 (Drosophila) (KLHL22), mRNA
Homo sapiens G protein-coupled receptor 161 (GPR161), transcript variant 2, mRNA
Homo sapiens G elongation factor, mitochondrial 1 (GFM1), nuclear gene encoding mitochondrial
Homo sapiens potassium intermediate/small conductance calcium-activated channel, subfamily
Homo sapiens Ras association (RalGDS/AF-6) domain family 2 (RASSF2), transcript variant 2,
Homo sapiens mitochondrial ribosomal protein L38 (MRPL38), nuclear gene encoding
Homo sapiens nuclear autoantigenic sperm protein (histone-binding) (NASP), transcript variant 1,
Homo sapiens GABA(A) receptor-associated protein-like 2 (GABARAPL2), mRNA
Homo sapiens melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor)
Homo sapiens isocitrate dehydrogenase 3 (NAD+) gamma (IDH3G), nuclear gene encoding
Homo sapiens small nuclear ribonucleoprotein D1 polypeptide 16 kDa (SNRPD1), mRNA
Homo sapiens growth associated protein 43 (GAP43), mRNA
Homo sapiens plexin D1 (PLXND1), mRNA
Homo sapiens melanoma antigen family D, 2 (MAGED2), transcript variant 2, mRNA
Homo sapiens chromosome 6 genomic contig, reference assembly
Homo sapiens chromosome 2 genomic contig, reference assembly
Homo sapiens chromosome 4 genomic contig, reference assembly
Homo sapiens SRY (sex determining region Y)-box 4 (SOX4), mRNA
Homo sapiens copine II (CPNE2), mRNA
Homo sapiens postmeiotic segregation increased 2-like 5 (PMS2L5), mRNA
Homo sapiens deltex 3 homolog (Drosophila) (DTX3), mRNA
Homo sapiens phosphoglycerate dehydrogenase like 1 (PHGDHL1), mRNA
Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase 6 (lysophosphatidic acid
Homo sapiens similar to CG12314 gene product (LOC201164), mRNA
Homo sapiens transmembrane protein 25 (TMEM25), mRNA
Homo sapiens sema domain, immunoglobulin domain (Ig), short basic domain, secreted,
Homo sapiens hypothetical protein FLJ22531 (FLJ22531), mRNA
Homo sapiens chromosome 22 open reading frame 28 (C22orf28), mRNA
Homo sapiens tissue factor pathway inhibitor 2 (TFPI2), mRNA
Homo sapiens surfeit 5 (SURF5), transcript variant c, mRNA
Homo sapiens coenzyme Q6 homolog, monooxygenase (S. cerevisiae) (COQ6), transcript
Homo sapiens coiled-coil domain containing 50 (CCDC50), transcript variant 1, mRNA
Homo sapiens microtubule-actin crosslinking factor 1 (MACF1), transcript variant 2, mRNA
Homo sapiens MCM3 minichromosome maintenance deficient 3 (S. cerevisiae) (MCM3), mRNA
Homo sapiens polycystic kidney disease 1 (autosomal dominant) (PKD1), transcript variant 2,
Homo sapiens ephrin-B2 (EFNB2), mRNA
Homo sapiens esterase D/formylglutathione hydrolase (ESD), mRNA
Homo sapiens ADP-ribosylation factor related protein 1 (ARFRP1), mRNA
Homo sapiens NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10, 42 kDa (NDUFA10),
Homo sapiens scavenger receptor class F, member 2 (SCARF2), transcript variant 1, mRNA
Homo sapiens ubiquitin-conjugating enzyme E2O (UBE2O), mRNA
Homo sapiens chromosome 19 open reading frame 43 (C19orf43), mRNA
Homo sapiens chromosome 1 open reading frame 89 (C1orf89), mRNA
Homo sapiens protein phosphatase 1, regulatory (inhibitor) subunit 2 (PPP1R2), mRNA
Homo sapiens zinc finger protein 71 (ZNF71), mRNA
Homo sapiens anaphase promoting complex subunit 5 (ANAPC5), mRNA
Homo sapiens family with sequence similarity 57, member B (FAM57B), mRNA
Homo sapiens polo-like kinase 1 (Drosophila) (PLK1), mRNA
Homo sapiens elaC homolog 2 (E. coli) (ELAC2), mRNA
Homo sapiens LTV1 homolog (S. cerevisiae) (LTV1), mRNA
Homo sapiens ecotropic viral integration site 5-like (EVI5L), mRNA
Homo sapiens zinc finger protein 502 (ZNF502), mRNA
Homo sapiens F-box and leucine-rich repeat protein 16 (F8XL16), mRNA
Homo sapiens PRP19/PSO4 pre-mRNA processing factor 19 homolog (S. cerevisiae) (PRPF19),
Homo sapiens PQ loop repeat containing 1 (PQLC1), mRNA
Homo sapiens solute carrier family 25 (mitochondrial carrier: glutamate), member 22
Homo sapiens zinc finger protein 420 (ZNF420), mRNA
Homo sapiens small nuclear ribonucleoprotein D3 polypeptide 18 kDa (SNRPD3), mRNA
Homo sapiens ribosomal protein L36a-like (RPL36AL), mRNA
Homo sapiens ribosomal protein S11 (RPS11), mRNA
Homo sapiens proteasome (prosome, macropain) 26S subunit, non-ATPase, 7 (Mov34 homolog)
Homo sapiens BCL2-related ovarian killer (BOK), mRNA
Homo sapiens vacuolar protein sorting 28 homolog (S. cerevisiae) (VPS28), transcript variant 1,
Homo sapiens aldolase A, fructose-bisphosphate (ALDOA), transcript variant 1, mRNA
Homo sapiens HIV-1 Tat interacting protein, 60 kDa (HTATIP), transcript variant 1, mRNA
Homo sapiens mitochondrial ribosomal protein S25 (MRPS25), nuclear gene encoding
Homo sapiens hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-
Homo sapiens ATP binding domain 3 (ATPBD3), mRNA
Homo sapiens ankyrin repeat domain 39 (ANKRD39), mRNA
Homo sapiens UDP-Gal: betaGal beta 1,3-galactosyltransferase polypeptide 6 (B3GALT6), mRNA
Homo sapiens chromosome 17 genomic contig, reference assembly
Homo sapiens chromosome 13 genomic contig, reference assembly
Homo sapiens zinc finger, MYM-type 2 (ZMYM2), mRNA
Homo sapiens chromosome 19 genomic contig, reference assembly
Homo sapiens zinc finger, HIT type 1 (ZNHIT1), mRNA
Homo sapiens splicing factor, arginine/serine-rich 9 (SFRS9), mRNA
Homo sapiens polymerase (DNA directed), lambda (POLL), mRNA
Homo sapiens LAG1 longevity assurance homolog 1 (S. cerevisiae) (LASS1), transcript variant 1,
Homo sapiens inhibitor of growth family, member 3 (ING3), transcript variant 1, mRNA
Homo sapiens chromosome 22 open reading frame 25 (C22orf25), mRNA
Homo sapiens ADP-ribosylation factor-like 3 (ARL3), mRNA
Homo sapiens zinc finger protein 346 (ZNF346), mRNA
Homo sapiens leucine rich repeat containing 4 (LRRC4), mRNA
Homo sapiens fibroblast growth factor (acidic) intracellular binding protein (FIBP), transcript
Homo sapiens zinc finger protein 428 (ZNF428), mRNA
Homo sapiens cleavage and polyadenylation specific factor 3-like (CPSF3L), transcript variant 1,
Homo sapiens phosphofructokinase, muscle (PFKM), mRNA
Homo sapiens progressive external ophthalmoplegia 1 (PEO1), mRNA
Homo sapiens amino-terminal enhancer of split (AES), transcript variant 2, mRNA
Homo sapiens PTK9L protein tyrosine kinase 9-like (A6-related protein) (PTK9L), mRNA
Homo sapiens activating signal cointegrator 1 complex subunit 3-like 1 (ASCC3L1), mRNA
Homo sapiens vasohibin 1 (VASH1), mRNA
Homo sapiens ubiquitin associated protein 2-like (UBAP2L), mRNA
Homo sapiens chromatin modifying protein 2B (CHMP2B), mRNA
Homo sapiens LY6/PLAUR domain containing 1 (LYPD1), mRNA
Homo sapiens solute carrier family 39 (zinc transporter), member 13 (SLC39A13), mRNA
Homo sapiens PDZ and LIM domain 2 (mystique) (PDLIM2), transcript variant 2, mRNA
Homo sapiens chromosome 15 open reading frame 17 (C15orf17), mRNA
Homo sapiens spastin (SPAST), transcript variant 1, mRNA
Homo sapiens farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase,
Homo sapiens mannose receptor, C type 2 (MRC2), mRNA
Homo sapiens zinc finger protein 646 (ZNF646), mRNA
Homo sapiens intraflagellar transport 140 homolog (Chlamydomonas) (IFT140), mRNA
Homo sapiens KIAA0195 (KIAA0195), mRNA
Homo sapiens ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit (oligomycin
Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 55 (DDX55), mRNA
Homo sapiens chromosome 3 open reading frame 60 (C3orf60), transcript variant 1, mRNA
Homo sapiens DNA segment on chromosome 21 (unique) 2056 expressed sequence
Homo sapiens E3 ubiquitin protein ligase, HECT domain containing, 1 (EDD1), mRNA
Homo sapiens neuroblastoma-amplified protein (NAG), mRNA
Homo sapiens polo-like kinase 3 (Drosophila) (PLK3), mRNA
Homo sapiens pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) (PPBP), mRNA
Homo sapiens transient receptor potential cation channel, subfamily C, member 4 associated
Homo sapiens solute carrier family 4, anion exchanger, member 3 (SLC4A3), transcript variant 2,
Homo sapiens receptor accessory protein 2 (REEP2), mRNA
Homo sapiens vacuolar protein sorting protein 18 (VPS18), mRNA
Homo sapiens TNF receptor-associated factor 2 (TRAF2), mRNA
Homo sapiens leucine rich repeat neuronal 5 (LRRN5), transcript variant 1, mRNA
Homo sapiens proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 (PSMD14),
Homo sapiens transmembrane protein 53 (TMEM53), mRNA
Homo sapiens DIP2 disco-interacting protein 2 homolog C (Drosophila) (DIP2C), mRNA
Homo sapiens peptidylprolyl isomerase B (cyclophilin B) (PPIB), mRNA
Homo sapiens endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 4
Homo sapiens butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine
Homo sapiens CDC-like kinase 3 (CLK3), transcript variant phclk3, mRNA
Homo sapiens GDP dissociation inhibitor 1 (GDI1), mRNA
Homo sapiens phosphate cytidylyltransferase 2, ethanolamine (PCYT2), mRNA
Homo sapiens polymerase (RNA) II (DNA directed) polypeptide B, 140 kDa (POLR2B), mRNA
Homo sapiens procollagen (type III) N-endopeptidase (PCOLN3), mRNA
Homo sapiens ryanodine receptor 2 (cardiac) (RYR2), mRNA
Homo sapiens SET translocation (myeloid leukemia-associated) (SET), mRNA
Homo sapiens transketolase (Wernicke-Korsakoff syndrome) (TKT), mRNA
Homo sapiens tumor protein, translationally-controlled 1 (TPT1), mRNA
Homo sapiens CASK interacting protein 2 (CASKIN2), mRNA
Homo sapiens peptidylprolyl isomerase D (cyclophilin D) (PPID), mRNA
Homo sapiens glucan (1,4-alpha-), branching enzyme 1 (glycogen branching enzyme, Andersen
Homo sapiens ketohexokinase (fructokinase) (KHK), transcript variant a, mRNA
Homo sapiens ornithine aminotransferase (gyrate atrophy) (OAT), nuclear gene encoding
Homo sapiens GTP binding protein 2 (GTPBP2), mRNA
Homo sapiens nerve growth factor receptor (TNFRSF16) associated protein 1 (NGFRAP1),
Homo sapiens SET and MYND domain containing 4 (SMYD4), mRNA
Homo sapiens protein arginine methyltransferase 2 (PRMT2), transcript variant 1, mRNA
Homo sapiens zinc finger protein 423 (ZNF423), mRNA
Homo sapiens astrotactin 2 (ASTN2), transcript variant 3, mRNA
Homo sapiens GRIP1 associated protein 1 (GRIPAP1), transcript variant 1, mRNA
Homo sapiens ADAM metallopeptidase domain 15 (metargidin) (ADAM15), transcript variant 6,
Homo sapiens ATP-binding cassette, sub-family A (ABC1), member 2 (ABCA2), transcript variant
Homo sapiens UDP-Gal: betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 4 (B4GALT4),
Homo sapiens choline kinase alpha (CHKA), transcript variant 1, mRNA
Homo sapiens ATG4 autophagy related 4 homolog B (S. cerevisiae) (ATG4B), transcript variant
Homo sapiens exosome component 5 (EXOSC5), mRNA
Homo sapiens splicing factor, arginine/serine-rich 2 (SFRS2), mRNA
Homo sapiens chromosome 16 open reading frame 7 (C16orf7), mRNA
Homo sapiens armadillo repeat containing, X-linked 3 (ARMCX3), transcript variant 3, mRNA
Homo sapiens death-associated protein (DAP), mRNA
Homo sapiens WD repeat domain 57 (U5 snRNP specific) (WDR57), mRNA
Homo sapiens benzodiazapine receptor (peripheral) associated protein 1 (BZRAP1), mRNA
Homo sapiens high-mobility group nucleosome binding domain 1 (HMGN1), mRNA
Homo sapiens ATPase, Ca++ transporting, plasma membrane 2 (ATP2B2), transcript variant 1,
Homo sapiens glutaminyl-tRNA synthetase (QARS), mRNA
Homo sapiens ATPase, Na+/K+ transporting, alpha 1 polypeptide (ATP1A1), transcript variant 1,
Homo sapiens PWP2 periodic tryptophan protein homolog (yeast) (PWP2H), mRNA
Homo sapiens SUMO-1 activating enzyme subunit 1 (SAE1), mRNA
Homo sapiens acyl-Coenzyme A dehydrogenase family, member 10 (ACAD10), mRNA
Homo sapiens A kinase (PRKA) anchor protein 8-like (AKAP8L), mRNA
Homo sapiens cytochrome b5 reductase 1 (CYB5R1), mRNA
Homo sapiens nuclear receptor subfamily 1, group H, member 3 (NR1H3), mRNA
Homo sapiens ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1,
Homo sapiens phosphofructokinase, liver (PFKL), transcript variant 1, mRNA
Homo sapiens sodium channel modifier 1 (SCNM1), transcript variant 1, mRNA
Homo sapiens ADP-ribosylation-like factor 6 interacting protein 4 (ARL6IP4), transcript variant 3,
Homo sapiens Enah/Vasp-like (EVL), mRNA
Homo sapiens glycerol-3-phosphate dehydrogenase 2 (mitochondrial) (GPD2), mRNA
Homo sapiens dihydropyrimidinase-like 2 (DPYSL2), mRNA
Homo sapiens eukaryotic translation initiation factor 3, subunit 6 interacting protein (EIF3S6IP),
Homo sapiens mannose-6-phosphate receptor binding protein 1 (M6PRBP1), mRNA
Homo sapiens chromosome 3 genomic contig, reference assembly
Homo sapiens chromosome 10 genomic contig, reference assembly
Homo sapiens mannosidase, alpha, class 1B, member 1 (MAN1B1), mRNA
Homo sapiens solute carrier family 41, member 1 (SLC41A1), mRNA
Homo sapiens kinetochore associated 2 (KNTC2), mRNA
Homo sapiens ADP-ribosylation-like factor 6 interacting protein 5 (ARL6IP5), mRNA
Homo sapiens similar to DNA segment, Chr 11, Brigham & Womens Genetics 0434 expressed
Homo sapiens leucine rich repeat neuronal 6A (LRRN6A), mRNA
Homo sapiens major histocompatibility complex, class I, A (HLA-A), mRNA
Homo sapiens paraneoplastic antigen MA1 (PNMA1), mRNA
Homo sapiens UTP11-like, U3 small nucleolar ribonucleoprotein, (yeast) (UTP11L), mRNA
Homo sapiens nuclear receptor subfamily 2, group F, member 1 (NR2F1), mRNA
Homo sapiens membrane-associated ring finger (C3HC4) 9 (MARCH9), mRNA
Homo sapiens calcium channel, voltage-dependent, alpha 1H subunit (CACNA1H), transcript
Homo sapiens chromosome 19 open reading frame 10 (C19orf10), mRNA
Homo sapiens BAI1-associated protein 2 (BAIAP2), transcript variant 3, mRNA
Homo sapiens NEL-like 2 (chicken) (NELL2), mRNA
Homo sapiens ST3 beta-galactoside alpha-2,3-sialyltransferase 4 (ST3GAL4), mRNA
Homo sapiens thioredoxin interacting protein (TXNIP), mRNA
Homo sapiens zinc finger, MIZ-type containing 2 (ZMIZ2), transcript variant 1, mRNA
Homo sapiens KIAA0907 (KIAA0907), mRNA
Homo sapiens dynein, axonemal, heavy chain 1 (DNAH1), mRNA
Homo sapiens bromodomain and PHD finger containing, 3 (BRPF3), mRNA
Homo sapiens kelch domain containing 5 (KLHDC5), mRNA
Homo sapiens density-regulated protein (DENR), mRNA
Homo sapiens DEP domain containing 5 (DEPDC5), transcript variant 1, mRNA
Homo sapiens zinc finger protein 382 (ZNF382), mRNA
Homo sapiens insulin-like growth factor binding protein 2, 36 kDa (IGFBP2), mRNA
Homo sapiens WW domain binding protein 5 (WBP5), transcript variant 1, mRNA
Homo sapiens Sfi1 homolog, spindle assembly associated (yeast) (SFI1), transcript variant 1,
Homo sapiens transmembrane emp24 protein transport domain containing 3 (TMED3), mRNA
Homo sapiens nuclear receptor co-repressor 2 (NCOR2), mRNA
Homo sapiens tubulin, gamma complex associated protein 6 (TUBGCP6), transcript variant 1,
Homo sapiens jumonji, AT rich interactive domain 1B (JARID1B), mRNA
Homo sapiens ceroid-lipofuscinosis, neuronal 5 (CLN5), mRNA
Homo sapiens dynein, light chain, Tctex-type 1 (DYNLT1), mRNA
Homo sapiens small nuclear ribonucleoprotein 70 kDa polypeptide (RNP antigen) (SNRP70),
Homo sapiens UDP-GlcNAc: betaGal beta-1,3-N-acetylglucosaminyltransferase-like 1
Homo sapiens t-complex 1 (TCP1), transcript variant 1, mRNA
Homo sapiens Meis1, myeloid ecotropic viral integration site 1 homolog 3 (mouse) (MEIS3),
Homo sapiens chromosome 22 open reading frame 9 (C22orf9), transcript variant 2, mRNA
Homo sapiens uridine-cytidine kinase 1-like 1 (UCKL1), mRNA
Homo sapiens PHD finger protein 19 (PHF19), transcript variant 2, mRNA
Homo sapiens chaperonin containing TCP1, subunit 7 (eta) (CCT7), transcript variant 1, mRNA
Homo sapiens centaurin, delta 3 (CENTD3), mRNA
Homo sapiens docking protein 5 (DOK5), mRNA
Homo sapiens DIRAS family, GTP-binding RAS-like 3 (DIRAS3), mRNA
Homo sapiens chaperonin containing TCP1, subunit 3 (gamma) (CCT3), transcript variant 2,
Homo sapiens nudix (nucleoside diphosphate linked moiety X)-type motif 21 (NUDT21), mRNA
Homo sapiens zinc finger protein 146 (ZNF146), mRNA
Homo sapiens clathrin, light polypeptide (Lca) (CLTA), transcript variant brain-specific, mRNA
Homo sapiens myelin transcription factor 1-like (MYT1L), mRNA
Homo sapiens golgi SNAP receptor complex member 2 (GOSR2), transcript variant A, mRNA
Homo sapiens WD repeat domain 5 (WDR5), transcript variant 1, mRNA
Homo sapiens hypothetical gene supported by AK094370 (LOC441208), mRNA
Homo sapiens CD81 molecule (CD81), mRNA
Homo sapiens crystallin, mu (CRYM), transcript variant 2, mRNA
Homo sapiens DEAD (Asp-Glu-Ala-As) box polypeptide 19B (DDX19B), transcript variant 3,
Homo sapiens potassium inwardly-rectifying channel, subfamily J, member 11 (KCNJ11), mRNA
Homo sapiens karyopherin alpha 2 (RAG cohort 1, importin alpha 1) (KPNA2), mRNA
Homo sapiens selenoprotein P, plasma, 1 (SEPP1), mRNA
Homo sapiens F-box and WD-40 domain protein 4 (FBXW4), mRNA
Homo sapiens chaperonin containing TCP1, subunit 3 (gamma) (CCT3), transcript variant 1,
Homo sapiens PMS2 postmeiotic segregation increased 2 (S. cerevisiae) (PMS2), transcript
Homo sapiens dickkopf homolog 3 (Xenopus laevis) (DKK3), transcript variant 1, mRNA
Homo sapiens nischarin (NISCH), mRNA
Homo sapiens alpha-2-macroglobulin (A2M), mRNA
Homo sapiens IMP (inosine monophosphate) dehydrogenase 2 (IMPDH2), mRNA
Homo sapiens RD RNA binding protein (RDBP), mRNA
Homo sapiens ribosomal protein S14 (RPS14), transcript variant 3, mRNA
Homo sapiens ribosomal protein L19 (RPL19), mRNA
Homo sapiens brain expressed, X-linked 1 (BEX1), mRNA
Homo sapiens progesterone receptor membrane component 1 (PGRMC1), mRNA
Homo sapiens interleukin-1 receptor-associated kinase 1 (IRAK1), transcript variant 2, mRNA
Homo sapiens leucine zipper-EF-hand containing transmembrane protein 1 (LETM1), mRNA
Homo sapiens ATP-binding cassette, sub-family F (GCN20), member 1 (ABCF1), transcript
Homo sapiens E4F transcription factor 1 (E4F1), mRNA
Homo sapiens ribosomal protein SA (RPSA), transcript variant 1, mRNA
Homo sapiens prolyl endopeptidase-like (PREPL), mRNA
Homo sapiens fibrinogen gamma chain (FGG), transcript variant gamma-B, mRNA
Homo sapiens CUG triplet repeat, RNA binding protein 1 (CUGBP1), transcript variant 3, mRNA
Homo sapiens ribosomal protein S7 (RPS7), mRNA
Homo sapiens vaccinia related kinase 1 (VRK1), mRNA
Homo sapiens ribosomal protein S16 (RPS16), mRNA
Homo sapiens alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5), mRNA
Homo sapiens ribosomal protein S23 (RPS23), mRNA
Homo sapiens similar to RIKEN cDNA B230118G17 gene (MGC19604), transcript variant 1,
Homo sapiens FSHD region gene 1 (FRG1), mRNA
Homo sapiens ligase III, DNA, ATP-dependent (LIG3), nuclear gene encoding mitochondrial
Homo sapiens diacylglycerol O-acyltransferase homolog 1 (mouse) (DGAT1), mRNA
Homo sapiens heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A)
Homo sapiens chromosome 19 open reading frame 6 (C19orf6), transcript variant 1, mRNA
Homo sapiens chromosome 17 open reading frame 62 (C17orf62), mRNA
Homo sapiens nuclear factor of activated T-cells, cytoplasmic calcineurin-dependent 2
Homo sapiens ubiquitin specific peptidase 11 (USP11), mRNA
Homo sapiens nucleolar protein 1, 120 kDa (NOL1), transcript variant 1, mRNA
Homo sapiens ubiquitin specific peptidase 48 (USP48), transcript variant 1, mRNA
Homo sapiens neuroblastoma breakpoint family, member 14 (NBPF14), mRNA
Homo sapiens gem (nuclear organelle) associated protein 4 (GEMIN4), mRNA
Homo sapiens glyceronephosphate O-acyltransferase (GNPAT), mRNA
Homo sapiens growth hormone inducible transmembrane protein (GHITM), mRNA
Homo sapiens mitogen-activated protein-binding protein-interacting protein (MAPBPIP), mRNA
Homo sapiens basic leucine zipper and W2 domains 2 (BZW2), mRNA
Homo sapiens FERM, RhoGEF and pleckstrin domain protein 2 (FARP2), mRNA
Homo sapiens lysosomal-associated membrane protein 1 (LAMP1), mRNA
Homo sapiens bifunctional apoptosis regulator (BFAR), mRNA
Homo sapiens GNAS complex locus (GNAS), transcript variant 4, mRNA
Homo sapiens TIA1 cytotoxic granule-associated RNA binding protein-like 1 (TIAL1), transcript
Homo sapiens ribosomal protein L14 (RPL14), transcript variant 1, mRNA
Homo sapiens ribosomal protein L23a (RPL23A), mRNA
Homo sapiens ribosomal protein L27 (RPL27), mRNA
Homo sapiens ribosomal protein L21 (RPL21), mRNA
Homo sapiens general transcription factor IIIC, polypeptide 2, beta 110 kDa (GTF3C2), transcript
Homo sapiens breakpoint duster region (BCR), transcript variant 1, mRNA
Homo sapiens cytoplasmic FMR1 interacting protein 2 (CYFIP2), transcript variant 2, mRNA
Homo sapiens eukaryotic translation elongation factor 1 beta 2 (EEF1B2), transcript variant 1,
Homo sapiens heterogeneous nuclear ribonucleoprotein A1 (HNRPA1), transcript variant 1,
Homo sapiens geranylgeranyl diphosphate synthase 1 (GGPS1), transcript variant 1, mRNA
Homo sapiens eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2), mRNA
Homo sapiens SECIS binding protein 2 (SECISBP2), mRNA
Homo sapiens solute carrier family 25, member 29 (SLC25A29), transcript variant 1, mRNA
Homo sapiens solute carrier family 25, member 29 (SLC25A29), transcript variant 2, mRNA
Homo sapiens ATPase, H+ transporting, lysosomal 21 kDa, V0 subunit b (ATP6V0B), transcript
Homo sapiens ATPase, H+ transporting, lysosomal 56/58 kDa, V1 subunit B2 (ATP6V1B2),
Homo sapiens NOL1/NOP2/Sun domain family, member 58 (NSUN5B), transcript variant 1,
Homo sapiens zinc finger, CCHC domain containing 14 (ZCCHC14), mRNA
Homo sapiens chromosome 2 genomic contig, reference assembly
Homo sapiens chromosome 2 genomic contig, alternate assembly (based on Celera assembly)
Homo sapiens chromosome 11 genomic contig, alternate assembly (based on Celera assembly)
Homo sapiens chromosome 15 genomic contig, alternate assembly (based on Celera assembly)
Homo sapiens chromosome 16 genomic contig, alternate assembly (based on Celera assembly)
Homo sapiens chromosome 22 genomic contig, reference assembly
Homo sapiens chromosome 22 genomic contig, alternate assembly (based on Celera assembly)
Homo sapiens hypothetical protein LOC55565 (LOC55565), mRNA
Homo sapiens proliferation-inducing protein 38 (PIG38), mRNA
Homo sapiens chromosome 1 open reading frame 75 (C1orf75), mRNA
Homo sapiens signal transducer and activator of transcription 3 interacting protein 1 (STATIP1),
Homo sapiens chromosome 6 open reading frame 64 (C6orf64), mRNA
Homo sapiens ADP-ribosylhydrolase like 2 (ADPRHL2), mRNA
Homo sapiens gelsolin (amyloidosis, Finnish type) (GSN), transcript variant 1, mRNA
Homo sapiens synaptic vesicle glycoprotein 2B (SV2B), mRNA
Homo sapiens PRP6 pre-mRNA processing factor 6 homolog (S. cerevisiae) (PRPF6), mRNA
Homo sapiens mitogen-activated protein kinase 3 (MAPK3), transcript variant 1, mRNA
Homo sapiens GTF2I repeat domain containing 2B (GTF2IRD2B), mRNA
Homo sapiens cortactin binding protein 2 (CTTNBP2), mRNA
Homo sapiens UDP-GlcNAc: betaGal beta-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1),
Homo sapiens centaurin, delta 2 (CENTD2), transcript variant 2, mRNA
Homo sapiens nuclear respiratory factor 1 (NRF1), transcript variant 2, mRNA
Homo sapiens netrin 4 (NTN4), mRNA
Homo sapiens ribosomal protein S6 kinase-like 1 (RPS6KL1), mRNA
Homo sapiens RNA binding motif protein 4 (RBM4), mRNA
Homo sapiens hydroxyacylglutathione hydrolase (HAGH), transcript variant 1, mRNA
Homo sapiens profilin 2 (PFN2), transcript variant 1, mRNA
Homo sapiens P450 (cytochrome) oxidoreductase (POR), mRNA
Homo sapiens REC8-like 1 (yeast) (REC8L1), mRNA
Homo sapiens ATP-binding cassette, sub-family B (MDR/TAP), member 8 (ABCB8), nuclear
| Number | Date | Country | Kind |
|---|---|---|---|
| 09171690.2 | Sep 2009 | EP | regional |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP2010/064510 | 9/29/2010 | WO | 00 | 6/22/2012 |
